Cellular Biomedicine Launching AlloJoin Knee OA Phase II Clinical Trial

Cellular Biomedicine launched a Phase II clinical trial for AlloJoin® off-the-shelf allogenic human adipose-derived mesenchymal progenitor cell (haMPC) therapy for knee osteoarthritis.

The trial will recruit 108 patients at six class 3AAA hospitals in China. The status of 3AAA indicates a highly-specialized facility in China's three-tier...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us